Literature DB >> 23441593

The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review.

B Anandasundaram1, D A Lane, S Apostolakis, G Y H Lip.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is commonly associated with vascular disease. Although atherosclerotic vascular disease (for example, defined as a myocardial infarction (MI), complex aortic plaque and peripheral arterial disease) has been proposed as a risk factor for a stroke, the co-existence of the two diseases increases the risk of future cardiovascular events. The objective of this study was to conduct a systematic review to assess the impact of atherosclerotic vascular disease on the primary end-point of a stroke, thromboembolism or mortality, in patients with AF.
METHODS: Literature searches were performed electronically, to identify studies published between January 1990and July 2012 examining stroke and thromboembolism in relation to AF and atherosclerotic vascular disease. Nineteen articles satisfied the pre-inclusion criteria. The bibliographies were subsequently screened to retrieve further relevant studies for this review.
RESULTS: Peripheral arterial disease significantly increased the stroke risk in all 10 observational studies, within a reported risk range of 1.3- to 2.5-fold. Complex aortic plaque on the descending aorta, as identified by trans-oesophageal echocardiography, was also a significant risk factor. Although a prior myocardial infarction (MI) was validated as a significant predictor of the primary end-point amongst five of the six studies, there was a degree of heterogeneity, owing to the marked difference in population sizes and the use of antithrombotic regimens between studies.
CONCLUSION: Atherosclerotic vascular disease (e.g. peripheral arterial disease, complex aortic plaque and prior MI) are significant predictors of a stroke, thromboembolism and mortality in subjects with AF.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Year:  2013        PMID: 23441593     DOI: 10.1111/jth.12177

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

Review 1.  Atherosclerosis and Atrial Fibrillation: Double Trouble.

Authors:  Mehran Abolbashari
Journal:  Curr Cardiol Rep       Date:  2022-01-06       Impact factor: 2.931

2.  Vascular Disease and Risk Stratification for Ischemic Stroke and All-Cause Death in Heart Failure Patients without Diagnosed Atrial Fibrillation: A Nationwide Cohort Study.

Authors:  Line Melgaard; Anders Gorst-Rasmussen; Lars Hvilsted Rasmussen; Gregory Y H Lip; Torben Bjerregaard Larsen
Journal:  PLoS One       Date:  2016-03-25       Impact factor: 3.240

Review 3.  Emerging Tools for Stroke Prevention in Atrial Fibrillation.

Authors:  Christos Voukalis; Gregory Y H Lip; Eduard Shantsila
Journal:  EBioMedicine       Date:  2016-01-15       Impact factor: 8.143

4.  CHADS2 score has a better predictive value than CHA2DS2-VASc score in elderly patients with atrial fibrillation.

Authors:  Yunli Xing; Qing Ma; Xiaoying Ma; Cuiying Wang; Dai Zhang; Ying Sun
Journal:  Clin Interv Aging       Date:  2016-07-14       Impact factor: 4.458

5.  Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study.

Authors:  Yutao Guo; Yutang Wang; Xiaoying Li; Zaoliang Shan; Xiangmin Shi; Guorong Xi; Gregory Y H Lip
Journal:  BMJ Open       Date:  2018-05-05       Impact factor: 2.692

6.  Time trends in adherence to guideline recommendations for anticoagulation therapy in patients with atrial fibrillation and myocardial infarction.

Authors:  Jarle Jortveit; Edvard L Sandberg; Are Hugo Pripp; Sigrun Halvorsen
Journal:  Open Heart       Date:  2022-04

7.  Prognostic Value of the CHA2DS2-VASc Score after Endovascular Therapy for Femoral Popliteal Artery Lesions.

Authors:  Yusuke Tomoi; Mitsuyoshi Takahara; Yoshimitsu Soga; Masahiko Fujihara; Osamu Iida; Daizo Kawasaki; Amane Kozuki; Kenji Ando
Journal:  J Atheroscler Thromb       Date:  2021-01-22       Impact factor: 4.928

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.